Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2023-09-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
上海荣正企业咨询服务（集团）股份有限公司关于恩威医药股份有限公司2023年限制性股票激励计划的财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to a 2023 Restricted Stock Incentive Plan for Enwei Pharmaceutical Co., Ltd. It contains detailed analysis and opinions on the stock incentive plan, including legal compliance, feasibility, scope of incentive targets, stock allocation, pricing, vesting conditions, and financial impact. The report is comprehensive, about 15,000 characters long, and includes financial and legal assessments but is not a full annual or quarterly financial report. It is not a simple announcement or certification but a detailed advisory report on a capital incentive plan. This fits best under the category of Capital/Financing Update (CAP), as it relates to stock-based compensation plans and capital structure changes through restricted stock incentives.
2023-09-26 Chinese
2023年限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as the '2023 Restricted Stock Incentive Plan Implementation Assessment Management Measures' for Enwei Pharmaceutical Co., Ltd. It details the purpose, principles, scope, assessment institutions, performance evaluation indicators, assessment periods, procedures, feedback, and management of the assessment results related to a restricted stock incentive plan. It is a policy or procedural document related to the management and assessment of a stock incentive plan, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or results, nor is it an announcement of a report. It is not related to board changes, voting results, or legal proceedings. The document is a governance-related internal policy document concerning stock incentive plan assessment and management, which fits best under Governance Information (CGR).
2023-09-26 Chinese
独立董事关于第二届董事会第十五次会议审议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the fifteenth meeting of the second board of directors of Enwei Pharmaceutical Co., Ltd. It focuses on the review and approval of a 2023 restricted stock incentive plan and its implementation assessment methods. The content is about governance and board-level decisions regarding stock incentive plans, including legal compliance and performance assessment. There is no financial data, earnings information, or report publication announcement. The document is not a full annual or interim report, nor is it a call transcript or audit report. It is a board/management information document related to board meeting decisions and opinions on corporate governance matters, specifically stock incentive plans. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short (1908 characters), but it contains substantive board opinions, not just an announcement or certification, so it is not RNS or RPA.
2023-09-26 Chinese
2023年限制性股票激励计划（草案）
Remuneration Information Classification · 95% confidence The document is titled "恩威医药股份有限公司 2023 年限制性股票激励计划（草案）" which translates to "Enwei Pharmaceutical Co., Ltd. 2023 Restricted Stock Incentive Plan (Draft)". It is a detailed draft plan for a restricted stock incentive program, including legal basis, management structure, scope of incentive recipients, stock source, quantity, allocation, effective period, grant date, vesting arrangements, grant price, conditions for grant and vesting, performance assessment, implementation procedures, and change procedures. The document references relevant laws and regulations such as the Company Law, Securities Law, Shenzhen Stock Exchange rules, and the China Securities Regulatory Commission. It is a comprehensive plan document related to equity incentives for employees and management, not a financial report, earnings release, or regulatory announcement. It is not a proxy solicitation or voting results announcement, but a detailed incentive plan draft. Therefore, the document fits best into the category of "Remuneration Information" which covers reports detailing compensation and incentive plans for executives and directors. The document length (15,000 characters) and detailed content confirm it is the plan itself, not just an announcement or summary.
2023-09-26 Chinese
关于召开2023年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2023 first extraordinary general meeting (临时股东大会) of shareholders for Enwei Pharmaceutical Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), agenda items for shareholder approval, registration details, and proxy forms. There is no financial data, earnings, or audit information presented. The document is not a report but a formal announcement and invitation to shareholders to attend and vote at the meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2023-09-26 Chinese
第二届监事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 14th meeting of the second Supervisory Board of Enwei Pharmaceutical Co., Ltd. It details the approval of a 2023 restricted stock incentive plan, its implementation assessment methods, and the verification of the incentive recipients list. The document includes voting results and states that these resolutions will be submitted to the 2023 first extraordinary general meeting of shareholders for approval. The content is procedural and governance-related, focusing on board decisions and compliance with laws and regulations. It does not contain financial statements, earnings data, or detailed financial analysis. The document length is short (2006 characters) and it is an announcement of board meeting resolutions rather than a full report or presentation. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management.
2023-09-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.